Lamisil reported to carry chance of liver failure
AUSTRALIA The Therapeutic Goods Administration has issued a warning about serious adverse side effects reported with Lamisil, a drug used for ringworm and nail fungal problems, according to published reports.
The medication is commonly prescribed to people who do not respond to topical fungal creams, but the regulator’s Adverse Drug Reactions Advisory Committee warns it can cause liver failure.
The committee has received 722 adverse event reports related to Lamisil, known generically as terbinafine, including 70 liver reactions, 61 implicating the tablet form as the sole suspected drug.
“Most of the reports document minor abnormalities of liver function but three describe fatal liver failure, 10 describe hepatitis, and 12 describe jaundice,’’ the committee’s latest drug reactions bulletin states.
The committee warned prescribers that the oral formulation should only be prescribed short-term and as a last resort. A spokesman for the drug’s manufacturer, Novartis, said that serious and life-threatening liver reactions were rare and well documented side effects of oral anti-fungal medications.
Parata launches PACMED C30 packaging technology
DURHAM, N.C. Parata Systems has launched its new product, the PACMED C30, which is a packaging technology used to extend the safety and convenience of its onePAC packaging system.
onePac is a strip that contains information like patients’ medications, patient names, pill descriptions and time of day to take a dose of the medication. On the strip, up to 19 lines of information can be held. The goal of the strips are to remind patients who take multiple medications when to take what medications and how much of each medication.
The PACMED C30 expands on the technology of the onePAC by combining multiple onePAC strips together for easy access by patients. PACMED C30 is efficient and accurate, generating up to 60 unit-dose or 50 multi-dose packages a minute.
“Adherence is a critical touch point in the circle of pharmacy care, and Parata’s launch of PACMED C30 offers an exciting new way for pharmacies to extend their care by improving patient adherence, safety and convenience,” says Tom Rhoads, executive vice president for customer and market strategies at Parata Systems.
Teva announces availablility of generic Fosamax
NORTH WALES, Pa. Teva has announced the introduction and availability of alendronate sodium tablets.
This is the generic version of the osteoporosis drug Fosamax by Merck. The drug will be available in 5 mg, 10 mg, 35 mg, 40 mg and 70 mg strengths.
“Our customers count on Teva for a continuous supply of new generic products,” stated John Denman, vice president of sales and marketing. “With the launch of alendronate sodium tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”